Korea's Hanmi And Merck Move To Sell Hanmi's Hypertension Drug In North America, China and Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The two companies also plan for MSD to market Amosartan in six Asia-Pacific countries under the Cozzar XQ brand, possibly as early as 2011, said a Hanmi official, who added that a deal in the region would generate $500 million in sales over the next 10 years.
You may also be interested in...
GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma
SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market
Korea's Anti-Rebate Laws Seen Sparking More Demand For MNC Products
SEOUL - Last week's passage of long-awaited "anti-rebate laws" that enable courts to punish both contributors and receivers of rebates, could trigger more demand from doctors to prescribe branded products from multinational companies, industry watchers said
Merck And Hanmi Partner In First Of A Kind Deal In South Korea
SEOUL - MSD Korea, Merck's South Korea branch, will sell a combination antihypertensive in South Korea in partnership with Hanmi Pharmaceutical, marking the first case in South Korea of a multinational company co-marketing a drug developed in part by a South Korean drug manufacturer